.jpg)
STAT+: Gene therapy to regenerate cardiac muscle after a heart attack passes a key test in pigs
By delivering a viral payload of gene silencers directly to the heart, scientists have developed…
Author: STAT
STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year
The controversial new Alzheimer’s drug from Biogen (BIIB) would be cost-effective only if priced between…
Opinion: Listen: A sister on watching the mental health care system fail her brother
In this week’s episode of the “First Opinion Podcast,” Lizzy Feliciano talks about her brother,…
Opinion: Copay assistance should count as part of patients’ cost sharing for medications
The Biden administration has made health equity a priority and it has been a constant…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
STAT+: The health tech tracker for the third quarter: 11 pivotal industry events to watch
The third quarter will answer crucial questions about the near-term future of digital health. Will…
12 lessons Covid-19 taught us about developing vaccines during a pandemic
The extraordinary drive to develop Covid-19 vaccines was like a moonshot — and like that fabled…
.jpg)
Demand is growing for continuous glucose monitoring for type 2 diabetes. Primary care doctors need to prepare
In the last year, Jai Smith has cycled through 13 primary care doctors. Ever since…
The WHO on ethical AI, Doximity’s ascent, & algorithms for IVF
You’re reading the web edition of Health Tech, STAT’s twice-weekly newsletter about how tech is…
Opinion: If Covid-19 vaccines can cause heart inflammation, caution should be warranted in those at risk
The remarkable development and rollout of Covid-19 vaccines will be hailed as a triumph of…
STAT+: STAT+ Conversations: A conversation about in vivo gene editing to treat rare disease
Editors note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: How Biogen and FDA formed a back channel to push an Alzheimer’s drug; Sanofi to dive into mRNA vaccine development
Top of the morning to you. And a steamy one, it is. In fact, there…
Operation Warp Speed — now, the ‘CAG’— is here to stay
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a…
Opinion: Public reporting: the first step in addressing the health care industry’s bloated carbon footprint
The health care industry focuses on healing. Yet its pursuit of that mission can cause…
Opinion: Florence Nightingale in the age of Covid-19
Last May marked the 200th anniversary of the birth of Florence Nightingale. That her bicentennial…
STAT+: Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug
It was perhaps the most contentious drug approval in decades, shocking drug company executives, insurance…
STAT+: Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?
Gilead Sciences (GILD) released top-line trial data for its Yescarta treatment that may allow the…
STAT+: Pharmalittle: Biogen Alzheimer’s drug will cost Medicare how much? Intellia data suggest a first for genome editing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Experts debate the value of digital coaching for type 2 diabetes
Even before the pandemic drove an extreme shift toward telemedicine, diabetes care was leading the…
Opinion: Biden won’t end cancer — or any other disease — by importing drug price controls from Europe
In his first budget, President Biden set aggressive health goals. “Let’s end cancer as we…
Opinion: Confronting a legacy of scarcity: a plan for reinvesting in U.S. public health
Public health in America is in crisis, a sad fact that the Covid-19 pandemic has…
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
The Food and Drug Administration’s decision to grant wide-ranging approval to the controversial, pricey new…
Opinion: An open letter to 2021 medical school graduates
To the medical school graduating class of 2021: As I write this, I imagine a…
Johnson & Johnson agrees to pay $230 million to settle opioid case in New York
On the eve of a widely anticipated trial, Johnson & Johnson (JNJ) has agreed to…
STAT+: In an about-face, Health Canada allows a controversial rare disease drug back on the market
In yet another twist in a complicated tale, Health Canada has reinstated approval of a…
STAT+: In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy
In a major milestone for the still-young field of genome editing, Intellia Therapeutics said Saturday that…
Opinion: India’s doctors — at home and abroad — face Covid’s unrelenting toll
Ravaged by Covid-19, India is desperately trying to contain a pandemic that has infected nearly…
STAT+: House leaders to investigate FDA approval and price of Biogen’s Alzheimer’s drug
WASHINGTON — The top House Democrats on two powerful committees on Friday announced an investigation…
Perna set to retire from Warp Speed later this summer
WASHINGTON — Gus Perna, the four-star Army general responsible for coordinating the U.S. coronavirus vaccine…
STAT+: Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows
The pharmaceutical industry has developed a “hidden web of policy influence” over members of the…
STAT+: As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat rare infection
Over the past few months, thousands of people in India who survived Covid-19 returned to…
Opinion: The PASTEUR Act can help win the war against superbugs
Look no further than the coronavirus pandemic to see an immediate and high-profile example of…
STAT+: Pharmalittle: Sanofi dengue vax endorsed by expert CDC panel; Pfizer recalls Chantix as it tests for possible carcinogens
And so, another working week will soon draw to a close. Not a moment too…
Opinion: For now, stem cells for Covid-19 are mostly a shot in the dark
The uncertainty over how to effectively treat Covid-19 is proving to be an opportunity for…
Opinion: The Covid-19 relief bill created 1,000 more residency slots for new doctors. Wealthy hospitals should be last in line to get them
The $1.9 trillion American Rescue Plan that President Biden signed into law in March includes…
After racing to help the world understand Covid-19, scientists grapple with how to pick up the research they put on hold
In the earliest days of the pandemic, it was the small, long-underfunded coterie of dedicated…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges
An expert panel voted Thursday to advise that the Centers for Disease Control and Prevention…
Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer
How does the FDA handle unprecedented decisions? What’s it like to go on “Good Morning…
STAT+: Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens
After finding potential carcinogens in some lots of Chantix, Pfizer (PFE) late last month halted…
The digital drug horizon, details on Verily’s Baseline, & VR for burn pain
You’re reading the web edition of Health Tech, STAT’s twice-weekly newsletter about how tech is…
STAT+: Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism
Hello, everyone, and nice to see you again after a day off. We can explain…
STAT+: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug…
Opinion: Next steps for wastewater testing to help end this pandemic — and prevent the next one
Essential data can be found in the most unexpected places, including the wastewater flowing freely…
Opinion: Breaths, deaths, and missed breaks: How counting defined my days as a pandemic nurse
I woke myself up the other morning counting out loud. Twenty-seven. Twenty-eight. Twenty-nine. Thirty. Rhythmic,…
STAT+: 5 companies harnessing AI for drug discovery to watch
A decade ago, the business of drug discovery changed forever. Machine learning researchers were beginning…
STAT+: FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm
WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six…
A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s…